0000950170-24-053000.txt : 20240503
0000950170-24-053000.hdr.sgml : 20240503
20240503164649
ACCESSION NUMBER: 0000950170-24-053000
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240501
FILED AS OF DATE: 20240503
DATE AS OF CHANGE: 20240503
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DICICCO WENDY F
CENTRAL INDEX KEY: 0001225165
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36288
FILM NUMBER: 24913999
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akari Therapeutics Plc
CENTRAL INDEX KEY: 0001541157
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 981034922
STATE OF INCORPORATION: X0
BUSINESS ADDRESS:
STREET 1: 22 BOSTON WHARF ROAD
STREET 2: FL 7
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: (646) 350-0702
MAIL ADDRESS:
STREET 1: 22 BOSTON WHARF ROAD
STREET 2: FL 7
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER COMPANY:
FORMER CONFORMED NAME: Celsus Therapeutics Plc.
DATE OF NAME CHANGE: 20130621
FORMER COMPANY:
FORMER CONFORMED NAME: Morria Biopharmaceuticals PLC
DATE OF NAME CHANGE: 20120201
4
1
ownership.xml
4
X0508
4
2024-05-01
0001541157
Akari Therapeutics Plc
AKTX
0001225165
DICICCO WENDY F
C/O AKARI THERAPEUTICS, PLC
22 BOSTON WHARF ROAD FL 7
BOSTON
MA
02210
false
true
false
false
Interim CFO
false
Ordinary Shares, par value $0.0001 per share
2024-05-01
4
A
false
158473915
0.00
A
158473915
D
These shares represent restricted stock units ("RSUs") granted under the Issuer's 2023 Equity Incentive Plan, with each such RSU representing the right to receive one ordinary share, par value $0.0001. One-hundered percent (100%) of the RSUs shall vest on May 1, 2025 (first anniversary of the date of grant), subject to the Reporting Person's continued service with the Issuer on the vesting date. Notwithstanding the foregoing, should the Issuer terminate the Reporting Person for any reason other than for cause prior to the vesting date, the RSUs will continue to vest through the first anniversary of the date of grant or be accelerated, at the Issuer's option.
/s/ Wendy F. DiCicco
2024-05-03